Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 13, 2009

Nine European Countries Sanction Six-Month Formulation of Debiopharm’s Prostate Cancer Medication

  • Debiopharm and its European marketing partner, Ipsen, confirmed regulatory approval of its prostate cancer drug in nine European countries: Germany (the reference member state), France, Austria, Finland, Norway, Belgium, Denmark, Spain, and The Netherlands. The sanction pertains to the six-month sustained-release formulation of Decapeptyl® and was given through the European decentralized procedure.

    The companies say that the this new formulation will probably be launched first in Germany, The Netherlands, and Spain. The new sustained-release LHRH agonist is indicated for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.

    Decapeptyl® is already available in monthly or quarterly sustained-release formulations as well as a daily formulation. The drugs are marketed worldwide for the treatment of advanced prostate cancer, endometriosis, precocious puberty, IVF applications, and uterine fibroids.

     



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »